Pressmeddelande -

Accelerator recruits key personnel

 

Accelerator recruits key personnel

Accelerators subsidiaries continue to recruit key personnel with industrial background. Spago Imaging has recruited Allan Simpson as Business Developer and Jörgen Buus Lassen to the company’s board of directors. In Synthetic MR Johan Sedihn has joined the board of directors.

”I’m very pleased that we have managed to recruits these highly qualified persons to our organisation. This doesn’t only strengthens our medical competes but also the commercial competes in our subsidiaries. For us this is also an indication that we are on the right track”, says Andreas Bunge CEO at Accelerator.

Allan Simpson has a background from GE Healthcare where he was Director of Strategic Alliances and Vice President for Research and Analysis within strategic alliances.

 

Jörgen Buus Lassen D.V.M. has over 25 years experience in the field of neuropharmacology. He is one of the founders of Neurosearch, one of Denmark’s most successful biopharmaceutical companies.

 

Johan Sedihn MSc is working at Elekta since 1993 and is chief of Elekta Oncology and member of the executive committee. SyntheticMR will benefit from Johan’s experience of global development of companies within the Elekta organisation.

 

During 2009 Spago Imaging produced their first MRI images with the SPAGO contrast media. The new the contrast media has the potential to significant improve the visualization and early detection of tumours.

 

Synthetic MR has in collaboration with Sectra started the launch of their time saving MRI software, SyMRI Suite.

 

 

For further information, please contact:

Andreas Bunge, CEO at Accelerator Nordic AB, phone +46 70 8 24 25 25

 

Spago Imaging AB develops nano-particle based contrast agents for diagnostic imaging with a focus on magnetic resonance imaging (MRI). Product development is focused on tumor and cardiac imaging. SPAGO enables molecular imaging and can provide faster imaging and better resolution with lower dosage. For more information, please visit, www.spagoimaging.se

 

SyntheticMR AB develops proprietary analytical and visualization tools to enable synthetic MRI which helps clinicians to dramatically reduce the time needed for MR-imaging, thereby increasing patient throughput.  Synthetic MR synthesizes all possible MRI parameters from a simple general scan, eliminating the current time consuming need to perform multiple scans.  Other advantages of synthetic MR are improved performance from current image analysis systems and the possibility to analyze fewer but more precise images. For more information, please visit, www.syntheticmr.se

 

 

Ämnen

  • Ekonomi, finans

Kategorier

  • accelerator
  • synthetic mr
  • spago
  • johan sedihn
  • jorgen buus lassen

Regioner

  • Stockholm

Accelerator Nordic AB is a group of developing companies based on Scandinavian Life Science. The company has an active majority position in a number of companies with Pharmaceutical and Medical technology products. The Accelerator Group is addressing therapeutics and imaging in large growth markets such as oncology, cardiology and drug delivery for orthopedic and dental implants. Products are in clinical phase II and initial commercialization phase. The business model is partnering or out-licensing. Accelerator Nordic is publicly traded on the Aktietorget exchange in Stockholm , Sweden.

For more information, please visit, www.acceleratorab.se

Kontakter

Relaterat innehåll

  • Accelerator rekryterar nyckelpersoner

    Accelerators dotterbolag fortsätter att knyta till sig internationellt meriterade nyckelpersoner inför kommersialiseringen av viktiga projekt. Spago Imaging har anställt Allan Simpson som chef för Business Development. Dotterbolaget förstärker samtidigt sin styrelse med Jörgen Buus Lassen medan Synthetic MR har valt in Johan Sedihn till sin styrelse.

  • Accelerator Bokslutskommuniké jan-dec 2009

    Bokslutskommuniké                                                        jan – dec 2009


    2009 i sammandrag
    Resultat efter finansiella poster uppgick till  - 10 889 Tkr (-9 038) Årets resultat uppgick till - 9 281 Tkr (-7 766) Resultat per aktie uppgick till -0,16 kr (- 0,16)

    Viktiga händelser under perioden


    I januari tillkännagav PledPharma public

  • Bioteknik och vårdbolag friskast på börsen

    Veckans Affärer har vaskat fram de hetaste bolagen på smålistorna. Bland de högst värderade hälsovårdsbolagen på Aktietorget finns ett annat investmentbolag, Accelerator, med en spännande portfölj. Där finns två medicinteknikbolag med produkter som är nära att lanseras och två läkemedelsprojekt i den andra prövningen på människa, klinisk fas II.